A discussion of the peptide’s pharmacological profile notes that PE-22-28 acts as a TREK-1 inhibitor with a significantly longer duration of action than its predecessor, Spadin. Research indicates its effects can last up to 23 hours, compared to only 7 hours for Spadin.